AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39112489 — intervention group
Group type: COMPARATOR
Intervention: Cohort with laboratory-confirmed gonococcal infection
Number of subjects: 50
Study 39112515 — intervention group
Group type: EXPERIMENTAL
Intervention: EuNmCV-5
Number of subjects: 60
Study 39112515 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM
Number of subjects: 60
Study 39112615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment (CI) with NBM synaptic density below 1.5 SD or 0.5 SD of the norm
Number of subjects: 120
Study 39112615 — intervention group
Group type: EXPERIMENTAL
Intervention: Synaptic density in NBM
Number of subjects: 120
Study 39112615 — intervention group
Group type: EXPERIMENTAL
Intervention: Synaptic loss in the NBM
Number of subjects: 120
Study 39112615 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurite density index in medial tracts
Number of subjects: 120
Study 39112615 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of synaptic density deviation from the norm
Number of subjects: 120
Study 39112628 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly for 12 months (N=10)
Number of subjects: 69
Study 39112628 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D alone for 12 months (N=8)
Number of subjects: 69
Study 39112634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 0
Study 39112634 — intervention group
Group type: COMPARATOR
Intervention: Standard volume hemofiltration (SVHF)
Number of subjects: 0
Study 39112757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-Heat self-warming blankets
Number of subjects: 15
Study 39112795 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM-MASH tool for scoring MASH histology
Number of subjects: 0
Study 39112795 — intervention group
Group type: EXPERIMENTAL
Intervention: Study treatment
Number of subjects: 0
Study 39112795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39112892 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Music-supported Therapy (eMST)
Number of subjects: 58
Study 39112892 — intervention group
Group type: COMPARATOR
Intervention: Conventional motor program (GRASP)
Number of subjects: 58
Study 39112976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 44
Study 39112976 — intervention group
Group type: COMPARATOR
Intervention: Irish Healthy Eating Guidelines (HEG)
Number of subjects: 44
Study 39112988 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameworks milled from PEEK blocks
Number of subjects: 36
Study 39112988 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameworks milled from soft metal blocks
Number of subjects: 36
Study 39112988 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameworks constructed with additive manufacturing (selective laser melting)
Number of subjects: 36
Study 39112988 — intervention group
Group type: COMPARATOR
Intervention: All groups (PEEK, soft metal, additive manufacturing)
Number of subjects: 36
Study 39113067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 2377
Study 39113067 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 2377
Study 39113067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (when LDL-C < 70 mg/dL)
Number of subjects: 2377
Study 39113067 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (when LDL-C < 70 mg/dL)
Number of subjects: 2377
Study 39113069 — intervention group
Group type: COMPARATOR
Intervention: Adult donor-RBCs (A-RBCs)
Number of subjects: 146
Study 39113069 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic CB-RBCs
Number of subjects: 146
Study 39113112 — intervention group
Group type: EXPERIMENTAL
Intervention: Panfungal-PCR screening methods
Number of subjects: 195
Study 39113112 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing and fungal genus identification by Sanger sequencing
Number of subjects: 195
Study 39113112 — intervention group
Group type: EXPERIMENTAL
Intervention: Panfungal-PCR screening
Number of subjects: 195
Study 39113181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) 3 times per week, consisting of 10×1 minute at 80%-100% heart rate reserve interspersed with 1 minute at 30% heart rate reserve (totaling 19 minutes)
Number of subjects: 82
Study 39113181 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) 3 times per week, consisting of 20-30 minutes at 40%-60% heart rate reserve
Number of subjects: 82
Study 39113190 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant AC-T chemotherapy with metformin
Number of subjects: 70
Study 39113266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for urinary incontinence treatment
Number of subjects: 10
Study 39114274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab (C1s inhibitor), biweekly doses for up to 1 year after Part A
Number of subjects: 39
Study 39114536 — intervention group
Group type: EXPERIMENTAL
Intervention: THC alone
Number of subjects: 250
Study 39114536 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD alone
Number of subjects: 250
Study 39114536 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD combination
Number of subjects: 250
Study 39114536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 39114536 — intervention group
Group type: EXPERIMENTAL
Intervention: THC alone, CBD alone, THC/CBD combination, Placebo
Number of subjects: 250
Study 39114670 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 118
Study 39114670 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 118
Study 39114821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-organ, multi-parametric magnetic resonance imaging (MRI) and circulating biomarkers
Number of subjects: 215
Study 39114821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests
Number of subjects: 215
Study 39114821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance (6 min walk test)
Number of subjects: 215
Study 39114821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition testing
Number of subjects: 215
Study 39114821 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfaction assessment
Number of subjects: 215
Study 39114821 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes collected up to 1 year from infection
Number of subjects: 215
Study 39114821 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging and circulating biomarkers
Number of subjects: 215
Study 39114821 — intervention group
Group type: COMPARATOR
Intervention: Comparison to controls (133 healthy volunteers)
Number of subjects: 215
Study 39114823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 100
Study 39114823 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 100
Study 39114870 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab treatment (administered once every 2 weeks)
Number of subjects: 87
Study 39114870 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab treatment
Number of subjects: 87
Study 39115062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipocalimab (30 or 45 mg per kilogram of body weight per week) administered from 14 to 35 weeks' gestation
Number of subjects: 13
Study 39115062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipocalimab treatment
Number of subjects: 13
Study 39115122 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse extraction site closure
Number of subjects: 1356
Study 39115122 — intervention group
Group type: COMPARATOR
Intervention: Vertical extraction site closure
Number of subjects: 1356
Study 39115302 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39115419 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-4157 (1-mg)
Number of subjects: 16
Study 39115419 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-4157 (1-mg) + Pembrolizumab (200-mg)
Number of subjects: 16
Study 39115479 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI angio-IMR >25
Number of subjects: 2212
Study 39115479 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI angio-IMR ≤25
Number of subjects: 2212
Study 39115479 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI angio-IMR
Number of subjects: 2212
Study 39115551 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSLE
Number of subjects: 3545
Study 39115583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose Prolotherapy and Deep Dry Needling (DDN)
Number of subjects: 40
Study 39115583 — intervention group
Group type: COMPARATOR
Intervention: Deep Dry Needling (DDN)
Number of subjects: 40
Study 39115608 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (information campaigns on AF diagnosis and therapies)
Number of subjects: 2769
Study 39115608 — intervention group
Group type: COMPARATOR
Intervention: Control group (recruited prior to intervention)
Number of subjects: 2769
Study 39115709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 416
Study 39115709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MASCC-score
Number of subjects: 416
Study 39115709 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonisation with Pichia kudriavzevii
Number of subjects: 416
Study 39115709 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolone use
Number of subjects: 416
Study 39115709 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline level
Number of subjects: 416
Study 39115709 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chronic obstructive pulmonary disease
Number of subjects: 416
Study 39115709 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonisation with fluconazole-resistant Candida
Number of subjects: 416
Study 39115845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) with usual oncological care
Number of subjects: 144
Study 39115845 — intervention group
Group type: COMPARATOR
Intervention: Usual supportive oncological care
Number of subjects: 144
Study 39115975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated (HF) PMRT (4256 cGy for 16 fractions)
Number of subjects: 400
Study 39115975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated (HF) PMRT
Number of subjects: 400
Study 39115975 — intervention group
Group type: COMPARATOR
Intervention: Conventionally Fractionated (CF) PMRT (5000 cGy for 25 fractions)
Number of subjects: 400
Study 39116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (RiaSTAP; CSL Behring)
Number of subjects: 36
Study 39116012 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate (control group)
Number of subjects: 36
Study 39116013 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Fluid Management (AFM) guided GDFT
Number of subjects: 86
Study 39116013 — intervention group
Group type: COMPARATOR
Intervention: Standard GDFT
Number of subjects: 86
Study 39116153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine therapy
Number of subjects: 30
Study 39116333 — intervention group
Group type: EXPERIMENTAL
Intervention: CETA-PWH (transdiagnostic counseling intervention)
Number of subjects: 60
Study 39116333 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 39116333 — intervention group
Group type: EXPERIMENTAL
Intervention: CETA-PWH (moderate dose)
Number of subjects: 60
Study 39116333 — intervention group
Group type: EXPERIMENTAL
Intervention: CETA-PWH (completers)
Number of subjects: 60
Study 39116333 — intervention group
Group type: EXPERIMENTAL
Intervention: CETA-PWH and Usual care
Number of subjects: 60
Study 39116385 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated maximal systolic BP (SBPmax) defined as ≥210 mmHg in males and ≥190 mmHg in females
Number of subjects: 589
Study 39116385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean SBP/W-slope
Number of subjects: 589
Study 39116385 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen uptake (VO2peak)
Number of subjects: 589
Study 39116385 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated SBPmax and below-median SBP/W-slope
Number of subjects: 589
Study 39116385 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-exaggerated SBPmax and above-median SBP/W-slope
Number of subjects: 589
Study 39116386 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39116423 — intervention group
Group type: EXPERIMENTAL
Intervention: PARITY intervention (wellness technology platform and community doula support)
Number of subjects: 60
Study 39116423 — intervention group
Group type: EXPERIMENTAL
Intervention: PARITY intervention
Number of subjects: 60
Study 39116423 — intervention group
Group type: COMPARATOR
Intervention: Informational control group
Number of subjects: 60
Study 39116435 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain training program (BrainHQ by Posit Science)
Number of subjects: 93
Study 39116435 — intervention group
Group type: COMPARATOR
Intervention: Active control program (computer games designed for entertainment, e.g., Solitaire)
Number of subjects: 93
Study 39116443 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual video postoperative visit
Number of subjects: 100
Study 39116443 — intervention group
Group type: COMPARATOR
Intervention: In-office postoperative visit
Number of subjects: 100
Study 39116448 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 4077
Study 39116448 — intervention group
Group type: EXPERIMENTAL
Intervention: ML models (eXtreme Gradient Boosting, Feedforward Neural Network, Logistic Regression, Support Vector Machine)
Number of subjects: 4077
Study 39116448 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological features identified by the Banff criteria
Number of subjects: 4077
Study 39116451 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based model for measuring preoperative kidney cortex volume from CT images
Number of subjects: 1074
Study 39116451 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly donors
Number of subjects: 1074
Study 39116486 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (IIV4) - three manufacturing lots, single dose.
Number of subjects: 1260
Study 39116661 — intervention group
Group type: EXPERIMENTAL
Intervention: Kahoot games and augmented reality (AR)
Number of subjects: 410
Study 39116661 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 410
Study 39116683 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus trastuzumab
Number of subjects: 5
Study 39116902 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 5·4 mg/kg
Number of subjects: 122
Study 39116902 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 6·4 mg/kg
Number of subjects: 122
Study 39116904 — intervention group
Group type: EXPERIMENTAL
Intervention: Butantan-DV (0.5 mL single dose)
Number of subjects: 16235
Study 39116904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16235
Study 39117359 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for detection of glaucoma progression
Number of subjects: 134
Study 39117359 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression model for detection of glaucoma progression
Number of subjects: 134
Study 39117402 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) using Freestyle Libre ProIQ device
Number of subjects: 100
Study 39117404 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT)
Number of subjects: 140
Study 39117404 — intervention group
Group type: COMPARATOR
Intervention: Regular treadmill walking (control)
Number of subjects: 140
Study 39117412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic arterial elastance (EaDyn) for weaning vasopressor support
Number of subjects: 114
Study 39117412 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure (MAP) for weaning vasopressor support
Number of subjects: 114
Study 39117415 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg daily aspirin
Number of subjects: 15076
Study 39117415 — intervention group
Group type: COMPARATOR
Intervention: 325 mg daily aspirin
Number of subjects: 15076
Study 39117415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 15076
Study 39117445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-induction-CS (adding etanercept for 24 weeks)
Number of subjects: 110
Study 39117445 — intervention group
Group type: COMPARATOR
Intervention: Standard-CS (adding leflunomide first)
Number of subjects: 110
Study 39117445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-induction-CS
Number of subjects: 110
Study 39117488 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-EPO (0.2, 0.4, 0.8, 1.6, 2.4, 3.6, or 4.8 µg/kg)
Number of subjects: 84
Study 39117488 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-EPO
Number of subjects: 84
Study 39117488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 39117670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg iv on day 1, carboplatin AUC 5 iv on day 1, etoposide 100 mg/m2 iv on days 1-3
Number of subjects: 0
Study 39117964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 3.75 mg/day for 7 days
Number of subjects: 111
Study 39117964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 39118020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures
Number of subjects: 25
Study 39118020 — intervention group
Group type: COMPARATOR
Intervention: Complete dentures
Number of subjects: 25
Study 39118035 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity coaching (5 sessions: 1 pre and 4 post surgery, intervention resource manual, wristband pedometer)
Number of subjects: 382
Study 39118035 — intervention group
Group type: COMPARATOR
Intervention: Physical activity self-monitoring alone (ASCO physical activity information, wristband pedometer)
Number of subjects: 382
Study 39118035 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity coaching
Number of subjects: 382
Study 39118035 — intervention group
Group type: COMPARATOR
Intervention: Physical activity self-monitoring alone
Number of subjects: 382
Study 39118070 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-change-material mattress (PCM)
Number of subjects: 113
Study 39118070 — intervention group
Group type: COMPARATOR
Intervention: Control (without PCM)
Number of subjects: 113
Study 39118082 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Vinegar
Number of subjects: 40
Study 39118082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylene diamine tetraacetic acid (17%) for five minutes
Number of subjects: 40
Study 39118095 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral membrane balloon technique
Number of subjects: 22
Study 39118095 — intervention group
Group type: COMPARATOR
Intervention: Densah burs
Number of subjects: 22
Study 39118135 — intervention group
Group type: EXPERIMENTAL
Intervention: robotic-assisted transabdominal preperitoneal (rTAPP)
Number of subjects: 150
Study 39118135 — intervention group
Group type: COMPARATOR
Intervention: laparoscopic TAPP
Number of subjects: 150
Study 39118136 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPATIA program (8-week guided Internet-delivered indicated prevention program)
Number of subjects: 152
Study 39118136 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) control condition
Number of subjects: 152
Study 39118150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pozelimab
Number of subjects: 10
Study 39118161 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM-C training program (immediate intervention)
Number of subjects: 100
Study 39118161 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (receiving CCM-C approximately 6 weeks later)
Number of subjects: 100
Study 39118264 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-nonachlor
Number of subjects: 2
Study 39118264 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-nonachlor
Number of subjects: 2
Study 39118264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirex
Number of subjects: 2
Study 39118264 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,4 DDE
Number of subjects: 2
Study 39118264 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive samples of organochlorines in fat
Number of subjects: 2
Study 39118264 — intervention group
Group type: COMPARATOR
Intervention: Urine samples
Number of subjects: 2
Study 39118360 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily use of 0.454% stannous fluoride (SnF)
Number of subjects: 90
Study 39118360 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (frequency of bioavailable SnF not specified)
Number of subjects: 90
Study 39118415 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 241
Study 39118415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 241
Study 39118415 — intervention group
Group type: EXPERIMENTAL
Intervention: History of iron overload
Number of subjects: 241
Study 39118415 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment interventions for neonatal complications
Number of subjects: 241
Study 39118415 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopenia/osteoporosis
Number of subjects: 241
Study 39118415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension
Number of subjects: 241
Study 39118415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic events
Number of subjects: 241
Study 39118424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse parental support using a symptom management mobile app for 3 months
Number of subjects: 0
Study 39118424 — intervention group
Group type: COMPARATOR
Intervention: Usual care available in the community
Number of subjects: 0
Study 39118878 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D lung reconstructions using open-source software
Number of subjects: 13
Study 39119004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's solution 5%, three oral drops thrice daily for 10 days
Number of subjects: 20
Study 39119627 — intervention group
Group type: EXPERIMENTAL
Intervention: People living with obesity (PLwO)
Number of subjects: 8000